Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients
Direct‐acting agents (DAAs) are highly efficient at treating hepatitis C virus (HCV) infections after kidney transplantation. Although drug agencies have recently warned of the risk of hepatitis B virus (HBV) reactivation after patients have received DAAs, reports have discrepant results in HBsAg‐po...
Gespeichert in:
| Veröffentlicht in: | Transplant infectious disease 2018-06, Vol.20 (3), p.e12864-n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e12864 |
| container_title | Transplant infectious disease |
| container_volume | 20 |
| creator | Pol, Stanislas Marion, Olivier Vallet‐Pichard, Anaïs Meritet, Jean‐François Sauné, Karine Alric, Laurent Kamar, Nassim |
| description | Direct‐acting agents (DAAs) are highly efficient at treating hepatitis C virus (HCV) infections after kidney transplantation. Although drug agencies have recently warned of the risk of hepatitis B virus (HBV) reactivation after patients have received DAAs, reports have discrepant results in HBsAg‐positive and HBsAg‐negative patients. We report on 3 cases of HBV reactivation that were detected after achieving a DAA‐associated sustained virological response in 3 kidney‐transplant recipients initially HBsAg‐negative. In the first case, retrospective virological analysis revealed that HBsAgs had become positive and HBV DNA was detectable before initiating DAA therapy. In the second and third cases, HBV reactivation occurred 2 months and more than 1 year after stopping anti‐HCV therapy. These cases underline the discrepancies and highlight the need for comprehensive information before making definitive conclusions regarding the causal link between DAAs and HBV reactivation. |
| doi_str_mv | 10.1111/tid.12864 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2011610896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2049914691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3534-5a0030ec266dedb582530b2fdc70c5094160b805eda507d7a152a336c9a7f4d43</originalsourceid><addsrcrecordid>eNp1kctOJCEUhslEM95mMS9gSNzoomwuBVUs7XacNjFxo24rNFCKdlMlUJqOm3kEn9EnmaOtLkxkwwnn4zsn-RH6TckhhTPK3h5SVsvyB9qkXKmCE8nW3uq6YKziG2grpVtCaKVK9RNtMCUoY5xuoqdjH53JL_-etck-XGMdsn_wUc8TlBbfuF5nn33CYwzPQ8L70_HVAY7ulX-AXhewD9h0oPChBZezGJDRdHKF77wNbgmdHHVI_Rzk8NP43ruQ0w5ab2GO-_V-b6PLkz8Xk2lxdv73dHJ0VhgueFkITQgnzjAprbMzUTPByYy11lTECKJKKsmsJsJZLUhlK00F05xLo3TVlrbk22h_5e1jdz-4lJuFT8bNYR3XDalhhFJJSa0koHtf0NtuiAG2A6pUipZSUaAOVpSJXUrRtU0f_ULHZUNJ85pIA4k0b4kAu_tuHGYLZz_JjwgAGK2ARz93y-9NzcXp8Ur5H18ql2s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2049914691</pqid></control><display><type>article</type><title>Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Pol, Stanislas ; Marion, Olivier ; Vallet‐Pichard, Anaïs ; Meritet, Jean‐François ; Sauné, Karine ; Alric, Laurent ; Kamar, Nassim</creator><creatorcontrib>Pol, Stanislas ; Marion, Olivier ; Vallet‐Pichard, Anaïs ; Meritet, Jean‐François ; Sauné, Karine ; Alric, Laurent ; Kamar, Nassim</creatorcontrib><description>Direct‐acting agents (DAAs) are highly efficient at treating hepatitis C virus (HCV) infections after kidney transplantation. Although drug agencies have recently warned of the risk of hepatitis B virus (HBV) reactivation after patients have received DAAs, reports have discrepant results in HBsAg‐positive and HBsAg‐negative patients. We report on 3 cases of HBV reactivation that were detected after achieving a DAA‐associated sustained virological response in 3 kidney‐transplant recipients initially HBsAg‐negative. In the first case, retrospective virological analysis revealed that HBsAgs had become positive and HBV DNA was detectable before initiating DAA therapy. In the second and third cases, HBV reactivation occurred 2 months and more than 1 year after stopping anti‐HCV therapy. These cases underline the discrepancies and highlight the need for comprehensive information before making definitive conclusions regarding the causal link between DAAs and HBV reactivation.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1111/tid.12864</identifier><identifier>PMID: 29512231</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>Activation ; Antiviral agents ; Antiviral drugs ; Deoxyribonucleic acid ; direct‐acting agents ; DNA ; HBsAg ; Health risk assessment ; Hepatitis ; Hepatitis B ; Hepatitis B surface antigen ; hepatitis B virus ; Hepatitis C ; hepatitis C virus ; Kidney transplantation ; Kidney transplants ; Patients ; Therapy ; Transplantation ; Transplants & implants ; Viruses</subject><ispartof>Transplant infectious disease, 2018-06, Vol.20 (3), p.e12864-n/a</ispartof><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3534-5a0030ec266dedb582530b2fdc70c5094160b805eda507d7a152a336c9a7f4d43</citedby><cites>FETCH-LOGICAL-c3534-5a0030ec266dedb582530b2fdc70c5094160b805eda507d7a152a336c9a7f4d43</cites><orcidid>0000-0003-1930-8964</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftid.12864$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftid.12864$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29512231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pol, Stanislas</creatorcontrib><creatorcontrib>Marion, Olivier</creatorcontrib><creatorcontrib>Vallet‐Pichard, Anaïs</creatorcontrib><creatorcontrib>Meritet, Jean‐François</creatorcontrib><creatorcontrib>Sauné, Karine</creatorcontrib><creatorcontrib>Alric, Laurent</creatorcontrib><creatorcontrib>Kamar, Nassim</creatorcontrib><title>Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>Direct‐acting agents (DAAs) are highly efficient at treating hepatitis C virus (HCV) infections after kidney transplantation. Although drug agencies have recently warned of the risk of hepatitis B virus (HBV) reactivation after patients have received DAAs, reports have discrepant results in HBsAg‐positive and HBsAg‐negative patients. We report on 3 cases of HBV reactivation that were detected after achieving a DAA‐associated sustained virological response in 3 kidney‐transplant recipients initially HBsAg‐negative. In the first case, retrospective virological analysis revealed that HBsAgs had become positive and HBV DNA was detectable before initiating DAA therapy. In the second and third cases, HBV reactivation occurred 2 months and more than 1 year after stopping anti‐HCV therapy. These cases underline the discrepancies and highlight the need for comprehensive information before making definitive conclusions regarding the causal link between DAAs and HBV reactivation.</description><subject>Activation</subject><subject>Antiviral agents</subject><subject>Antiviral drugs</subject><subject>Deoxyribonucleic acid</subject><subject>direct‐acting agents</subject><subject>DNA</subject><subject>HBsAg</subject><subject>Health risk assessment</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B surface antigen</subject><subject>hepatitis B virus</subject><subject>Hepatitis C</subject><subject>hepatitis C virus</subject><subject>Kidney transplantation</subject><subject>Kidney transplants</subject><subject>Patients</subject><subject>Therapy</subject><subject>Transplantation</subject><subject>Transplants & implants</subject><subject>Viruses</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kctOJCEUhslEM95mMS9gSNzoomwuBVUs7XacNjFxo24rNFCKdlMlUJqOm3kEn9EnmaOtLkxkwwnn4zsn-RH6TckhhTPK3h5SVsvyB9qkXKmCE8nW3uq6YKziG2grpVtCaKVK9RNtMCUoY5xuoqdjH53JL_-etck-XGMdsn_wUc8TlBbfuF5nn33CYwzPQ8L70_HVAY7ulX-AXhewD9h0oPChBZezGJDRdHKF77wNbgmdHHVI_Rzk8NP43ruQ0w5ab2GO-_V-b6PLkz8Xk2lxdv73dHJ0VhgueFkITQgnzjAprbMzUTPByYy11lTECKJKKsmsJsJZLUhlK00F05xLo3TVlrbk22h_5e1jdz-4lJuFT8bNYR3XDalhhFJJSa0koHtf0NtuiAG2A6pUipZSUaAOVpSJXUrRtU0f_ULHZUNJ85pIA4k0b4kAu_tuHGYLZz_JjwgAGK2ARz93y-9NzcXp8Ur5H18ql2s</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Pol, Stanislas</creator><creator>Marion, Olivier</creator><creator>Vallet‐Pichard, Anaïs</creator><creator>Meritet, Jean‐François</creator><creator>Sauné, Karine</creator><creator>Alric, Laurent</creator><creator>Kamar, Nassim</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1930-8964</orcidid></search><sort><creationdate>201806</creationdate><title>Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients</title><author>Pol, Stanislas ; Marion, Olivier ; Vallet‐Pichard, Anaïs ; Meritet, Jean‐François ; Sauné, Karine ; Alric, Laurent ; Kamar, Nassim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3534-5a0030ec266dedb582530b2fdc70c5094160b805eda507d7a152a336c9a7f4d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Activation</topic><topic>Antiviral agents</topic><topic>Antiviral drugs</topic><topic>Deoxyribonucleic acid</topic><topic>direct‐acting agents</topic><topic>DNA</topic><topic>HBsAg</topic><topic>Health risk assessment</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B surface antigen</topic><topic>hepatitis B virus</topic><topic>Hepatitis C</topic><topic>hepatitis C virus</topic><topic>Kidney transplantation</topic><topic>Kidney transplants</topic><topic>Patients</topic><topic>Therapy</topic><topic>Transplantation</topic><topic>Transplants & implants</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pol, Stanislas</creatorcontrib><creatorcontrib>Marion, Olivier</creatorcontrib><creatorcontrib>Vallet‐Pichard, Anaïs</creatorcontrib><creatorcontrib>Meritet, Jean‐François</creatorcontrib><creatorcontrib>Sauné, Karine</creatorcontrib><creatorcontrib>Alric, Laurent</creatorcontrib><creatorcontrib>Kamar, Nassim</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pol, Stanislas</au><au>Marion, Olivier</au><au>Vallet‐Pichard, Anaïs</au><au>Meritet, Jean‐François</au><au>Sauné, Karine</au><au>Alric, Laurent</au><au>Kamar, Nassim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2018-06</date><risdate>2018</risdate><volume>20</volume><issue>3</issue><spage>e12864</spage><epage>n/a</epage><pages>e12864-n/a</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>Direct‐acting agents (DAAs) are highly efficient at treating hepatitis C virus (HCV) infections after kidney transplantation. Although drug agencies have recently warned of the risk of hepatitis B virus (HBV) reactivation after patients have received DAAs, reports have discrepant results in HBsAg‐positive and HBsAg‐negative patients. We report on 3 cases of HBV reactivation that were detected after achieving a DAA‐associated sustained virological response in 3 kidney‐transplant recipients initially HBsAg‐negative. In the first case, retrospective virological analysis revealed that HBsAgs had become positive and HBV DNA was detectable before initiating DAA therapy. In the second and third cases, HBV reactivation occurred 2 months and more than 1 year after stopping anti‐HCV therapy. These cases underline the discrepancies and highlight the need for comprehensive information before making definitive conclusions regarding the causal link between DAAs and HBV reactivation.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29512231</pmid><doi>10.1111/tid.12864</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1930-8964</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1398-2273 |
| ispartof | Transplant infectious disease, 2018-06, Vol.20 (3), p.e12864-n/a |
| issn | 1398-2273 1399-3062 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2011610896 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Activation Antiviral agents Antiviral drugs Deoxyribonucleic acid direct‐acting agents DNA HBsAg Health risk assessment Hepatitis Hepatitis B Hepatitis B surface antigen hepatitis B virus Hepatitis C hepatitis C virus Kidney transplantation Kidney transplants Patients Therapy Transplantation Transplants & implants Viruses |
| title | Direct‐acting antivirals and hepatitis B virus (HBV) reactivation in co‐infected HBV/HCV kidney‐transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T07%3A19%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Direct%E2%80%90acting%20antivirals%20and%20hepatitis%20B%20virus%20(HBV)%20reactivation%20in%20co%E2%80%90infected%20HBV/HCV%20kidney%E2%80%90transplant%20recipients&rft.jtitle=Transplant%20infectious%20disease&rft.au=Pol,%20Stanislas&rft.date=2018-06&rft.volume=20&rft.issue=3&rft.spage=e12864&rft.epage=n/a&rft.pages=e12864-n/a&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1111/tid.12864&rft_dat=%3Cproquest_cross%3E2049914691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2049914691&rft_id=info:pmid/29512231&rfr_iscdi=true |